FindTrial
Sign In

Study on the Mechanism and Targeted Intervention of CD93 in Regulating Neovascularization of Retinopathy of Prematurity

Study on the Mechanism and Targeted Intervention of CD93 in Regulating Neovascularization of Retinopathy of Prematurity

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109607
Enrollment
Unknown
Registered
2025-09-23
Start date
2025-09-30
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of Prematurity

Interventions

Observation Group of children with Retinopathy of Prematurity:None

Sponsors

The Second Affliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Infants diagnosed with ROP or hemangioma; 2. Preterm infants with gestational age < 32 weeks or birth weight < 2000g; 3. Patients are willing to sign ethical informed consent.

Exclusion criteria

Exclusion criteria: 1. Infectious diseases such as HIV, syphilis, hepatitis or cytomegalovirus infection; 2. Major systemic diseases, such as congenital metabolic diseases, blood diseases, etc. 3. Other ocular abnormalities, such as congenital cataract, glaucoma or defect; 4. Major general deformity; 5. Abnormal coagulation status.

Design outcomes

Primary

MeasureTime frame
Plasma CD93 level;Detection of CD93 gene polymorphism in blood cells;—

Countries

China

Contacts

Public ContactZhongyu Zhang

The Second Affliated Hospital of Harbin Medical University

1971714018@qq.com+86 138 4508 0590

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026